Vertex Pharmaceuticals Incorporated

Who: Eli Lilly/SiteOne Therapeutics What: Lilly has agreed to acquire privately held SiteOne and its Phase II-ready Nav1.8 inhibitor for pain for up to $1bn. Why: Pain is an area of therapeutic f

The first clinical data from CRISPR Therapeutics’ in vivo gene-editing candidate, CTX310, look promising, with steep drops in low-density lipoprotein (LDL)-cholesterol and triglyceride levels. The r

Perhaps investors just need to wait another quarter or two to get a better read on the launch trajectories for Vertex Pharmaceuticals’ two newest products, but first quarter 2025 performance for its c

Biopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso